Sign in
Active, not recruitingNo phase

Neuromuscular Electrical Stimulation For The Treatment of Diabetic Neuropathy

Key facts

Who runs it
Imperial College London
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
65 people enrolled
Started
22 Aug 2023
Ended
30 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Revitive Medic Coach (Actegy Ltd)
  • Sham Revitive Medic Coach (Actegy Ltd)
Record updated
9 April 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Aged ≥18 (no upper limit)
  • Diagnosis of type 1 or type 2 diabetes based on World Health Organisation (WHO) definition
  • Diagnosis of diabetic neuropathy based on validated screening questionnaire Michigan Neuropathy Screening Instrument score of ≥4
  • Access to internet at home to use the Revitive App (study smartphones will be provided)

Who cannot take part

  • Implanted electronic, cardiac or defibrillator device
  • Severe vascular disease requiring invasive intervention
  • Being treated for, or have the symptoms of, an existing deep vein thrombosis (DVT)
  • Lacks capacity to provide informed consent
  • Pregnant
  • Other cause of peripheral neuropathy
  • Current foot ulceration
  • Used a neuromuscular electrical stimulation (NMES) device within 1 year of randomisation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Diabetic neuropathy (DN) is the most common complication of diabetes, affecting almost 50% of people with diabetes over the course of their lives. Symptoms vary from numbness to burning, aching and hypersensitivity in the lower limbs, indicative of sensory nerve loss. Motor neurons can also be affected, leading to muscle weakness and mobility issues, thus preventing patients from engaging in daily routines. Further sequelae include foot ulceration and Charcot neuroarthropathy, which are risk factors for lower limb amputation and mortality. In the United Kingdom, the annual costs of DN alone exceed £300 million, with further complications expected to cost an additional £1 billion. Currently, management strategies for DN focus on prevention and pain management. Neuromuscular electrical stimulation (NMES) is a novel nonpharmacological intervention for people with DN. NMES is the application of electrical impulses which are of sufficiency intensity to improve artificial contraction of the muscle tissue and may help with DN by improving nerve conductivity through direct stimulation of the nerves.

The 2 groups in the trial

  • Control groupSham treatment, for comparison

    Standard of Care + Sham Revitive Medic Coach (Sham Neuromuscular Electrical Stimulation Device) for 12 weeks

    Treatment: Sham Revitive Medic Coach (Actegy Ltd)

  • Intervention groupExisting treatment, for comparison

    Standard of Care + Revitive Medic Coach (Neuromuscular Electrical Stimulation Device) for 12 weeks

    Treatment: Revitive Medic Coach (Actegy Ltd)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neuromuscular Electrical Stimulation For The Treatment Of Diabetic Neuropathy: A Multicentre, Double-blind, Pilot, Randomised, Sham-controlled Trial
Record updated
9 April 2025